Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2019
Corbyn pledges to create state-run generics firm to cut drug prices
22 November 2019 - Labour leader Jeremy Corbyn has included in the party’s election manifesto plans to create a state-run ...
Posted by Michael Wonder on 20 Apr 2019
Expanding the scope of costs and benefits for economic evaluations in health: some words of caution
18 April 2019 - Discussions regarding the appropriate scope of costs and benefits for inclusion in economic evaluation in healthcare have ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 12 Nov 2018
Biosimilar drugs promise to slash health care costs in rich countries
8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 22 Mar 2018
Affordability of new technologies: the next frontier
22 March 2018 - Affordability, or rather a lack of it, has become a new buzzword in health policy. It is ...
Posted by Michael Wonder on 05 Mar 2018
NHS prescription charges are rising – here’s how to keep them down
3 March 2016 - Here’s what you need to know about the increase – and how to get cheaper everyday medicines. ...
Posted by Michael Wonder on 26 Feb 2018
NHS could claw back £502m if Lyrica ruling upheld, study finds
26 February 2018 - The NHS could reclaim up to £502 million in excess prescribing costs relating to Pfizer’s pregabalin ...
Posted by Michael Wonder on 31 Jan 2018
CDF to save NHS £140m over five years
31 January 2018 - At least £140 million is expected to be released into the NHS over the next five ...
Posted by Michael Wonder on 20 Dec 2017
'Drugs are too expensive for the NHS – and people are paying with their lives’
20 December 2017 - Don’t blame the NHS for denying vital medication, say members of a new activist group, Just Treatment. ...
Posted by Michael Wonder on 06 Jul 2017
One in three RA patients rejecting meds because of cost
6 July 2017 - One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed ...
Posted by Michael Wonder on 23 Sep 2016
UK audit shows infliximab biosimilars are safe, effective, and cheap
22 September 2016 - Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (Remicade)—are ...
Posted by Michael Wonder on 05 Jul 2016
Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal
3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...